respiratory

R&D

Human challenge trials offer a complementary approach, and hVIVO has been at the forefront of this field for decades.

News

Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

News

GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.

News

GSK scores a first approval in the UK for new severe asthma and CRSwNP therapy Exdensur, but a second in the US covers the asthma indication only.

News

GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.

News

In its second pipeline-expanding deal in 24 hours, GSK has licensed rights to a drug for COPD from US biotech Empirico for $85m upfront.